



## Mithra announces updates to its 2024 financial calendar

**Liege, Belgium, 28 March 2024 – 08:00 CET** – Mithra (Euronext Brussels: MITRA) (the “**Company**”), a company dedicated to women’s health, announces today updates to its financial calendar for 2024.

Considering the timeline of the [previously announced](#) Monetization Process, the Company, in agreement with its statutory auditor, has decided to postpone the publication of its Annual Report 2023 (which was initially envisaged to take place on 16 April 2024) to 30 April 2024, as by that time the Company expects to be in a position to provide more clarity and transparency on the ongoing Monetization Process.

For the same reason, the publication of the convening notice for the Company’s Annual General Meeting (with all legally required information) will be postponed to 30 April 2024, resulting in the postponement of the date of the Annual General Meeting from 16 May 2024 to the 30 May 2024. The financial calendar is thus adapted as follows:

- **8 March 2024: Full year results 2023 - completed**
- **30 April 2024: Annual report 2023 (changed from 16 April 2024)**
- **30 May 2024: General Shareholders’ Meeting (changed from 16 May 2024)**
- **26 September 2024: Half year results 2024**

The Company will continue to update the market as appropriate with respect to the Monetization Process.

The adapted financial calendar and all corporate information on the Company (financial statements, events or corporate presentations, ...) are available on the Company’s website in the Investors’ section ([mithra.com/en/investors](https://mithra.com/en/investors)).

For more information, please contact:

**Mithra Pharmaceuticals SA**

Alex Sokolowski, PhD  
Head of IR & Communications  
[investorrelations@mithra.com](mailto:investorrelations@mithra.com)  
+32 (0)4 349 28 22

Frédérique Depraetere  
Communications Director  
[info@mithra.com](mailto:info@mithra.com)  
+32 (0)4 349 28 22

**About Mithra**

Mithra Pharmaceuticals SA (Euronext: MITRA) is a Belgian biopharmaceutical company dedicated to transforming women's health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill ESTELLE<sup>®</sup>, Mithra is now focusing on its second product DONESTA<sup>®</sup>, the next-generation hormone therapy. Mithra also offers partners a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals (vials, pre-filled syringes or cartridges) at its technological platform Mithra CDMO. Active in more than 100 countries around the world, is headquartered in Liège, Belgium. [www.mithra.com](http://www.mithra.com)

ESTELLE<sup>®</sup> and DONESTA<sup>®</sup> are registered trademarks of Mithra Pharmaceuticals or one of its affiliates.

**Important information**

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates", "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

News Alerts

Subscribe to our mailing list on [investors.mithra.com](http://investors.mithra.com) to receive press releases by email or follow us on social media:

[LinkedIn](#) • [X](#) • [Facebook](#)